Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy
- 3 June 2015
- journal article
- Published by Wiley in BJU International
- Vol. 117 (1) , 118-125
Abstract
Objective: To describe both clinical and pathological response rates, survival, and predictors of survival when using contemporary perioperative chemotherapy and surgical resection for patients with regionally advanced squamous cell carcinoma ( SCC ) of the penis. Patients and Methods: Retrospective review of all patients diagnosed with SCC of the penis and regional lymph node metastases that were treated with chemotherapy with the intent to undergo lymphadenectomy. Clinical and pathological responses were reported. Recurrence‐free and overall survival was estimated using K aplan– M eier analysis. Cox proportional hazards regression was used to assess factors for survival. Results: In all, 61 patients were identified, of which 54 (90%) received chemotherapy with paclitaxel/ifosfamide/cisplatin. In all, 39 patients (65%) had either a partial ( PR ) or complete response ( CR ) to chemotherapy. The 5‐year survival varied significantly ( P = 0.045–0.001) among patients achieving a CR / PR (50%), stable disease (25%), and progression (7.7%). In all, 10 patients (16.4%) were rendered pN0 with combined therapy and 20 patients (33%) were alive and disease free at a median follow‐up of 67 months, while 32 (52%) died from disease. Long‐term survival was associated with response to chemotherapy and favourable pathological findings after resection. Conclusion: Contemporary chemotherapy resulted in clinically significant responses among patients with regionally advanced penile cancer. About 50% of such patients with an objective response to chemotherapy who undergo consolidative lymphadenectomy will remain alive at 5 years.Keywords
Funding Information
- National Cancer Institute (P30 CA016672)
This publication has 30 references indexed in Scilit:
- Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)British Journal of Cancer, 2013
- Prognostic Significance of Extranodal Extension in Patients With Pathological Node Positive Penile CarcinomaJournal of Urology, 2010
- Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II StudyJournal of Clinical Oncology, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)Annals of Oncology, 2008
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Neoadjuvant Chemotherapy in Advanced Penile CarcinomaEuropean Urology, 2007
- Pelvic Lymph Node Dissection for Penile Carcinoma: Extent of Inguinal Lymph Node Involvement as an Indicator for Pelvic Lymph Node Involvement and SurvivalJournal of Urology, 2007
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958